Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Sarepta Therapeutics (SRPT) is back in focus after releasing early Phase 1/2 data for two investigational siRNA therapies, SRP-1001 and SRP-1003, targeting rare neuromuscular diseases with significant unmet medical need. See our latest analysis for Sarepta Therapeutics. The early siRNA data arrives after a sharp rebound in the shares, with a 1-day share price return of 34.98% and a 7-day share price return of 38.52% at a last close of $23.77. However, the 1-year total shareholder return is a 67.38% decline, so recent momentum contrasts with weaker longer term results as investors reassess both pipeline potential and perceived risks. If this kind of clinical news has your attention, it can be worth broadening your search to other rare disease and biotech names through our curated list of 36 healthcare AI stocks With the shares rebounding sharply yet still carrying a 1 year total return decline of 67.38%, and trading at a sizeable intrinsic discount, investors now have to ask:
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics (SRPT) had its price target raised by Citigroup Inc. from $9.00 to $13.00. They now have a "sell" rating on the stock.MarketBeat
- Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics (SRPT) had its "underperform" rating reaffirmed by Needham & Company LLC.MarketBeat
- Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results [Yahoo! Finance]Yahoo! Finance
- Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business Wire
SRPT
Earnings
- 2/25/26 - Miss
SRPT
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- SRPT's page on the SEC website